The FDA granted orphan designation to a treatment of acute myeloid leukemia being developed by Cero Therapeutics (CERO), according to a post to the agency’s website.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- CERo Therapeutics Conducts Reverse Stock Split to Meet Nasdaq Requirements
- CERo Therapeutics Holdings Inc trading halted, news pending
- CERo Therapeutics Announces Reverse Stock Split
- Cero Therapeutics announces 1-for-20 reverse stock split
- Upcoming Stock Splits This Week (June 9 to June 13) – Stay Invested